<DOC>
	<DOCNO>NCT03025308</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability filgotinib participant complete one parent study filgotinib rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Long Term Extension Study Assess Safety Efficacy Filgotinib Adults With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Key Males female may benefit filgotinib judge investigator AND complete Gilead sponsor filgotinib parent study RA outline : Have complete GSUS4170301 , GSUS4170302 GSUS4170303 study drug OR Have complete GSUS4170302 standard care therapy due RA nonresponder status Females childbearing potential must negative pregnancy test prior first dose study drug long term extension ( LTE ) Males females childbearing potential engage heterosexual intercourse must agree protocolapproved method contraception Key Diagnosis autoimmune inflammatory joint disease RA , would put participant risk participate study would interfere study assessments/data interpretation , per judgment investigator Known hypersensitivity study drug excipients Any medical condition would put participant risk participate study would interfere study assessments/data interpretation , per judgment investigator NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>